Research Events

SMARCB1 Hope 2023 Symposium

Under the guidance of Olivier Delattre and Franck Bourdeaut from the Curie Institute in Paris, the groundbreaking SMARCB1 Hope 2023 Symposium gathered 30 internationally renowned experts in the SMARCB1 cancer field: oncology researchers, clinicians, scientists, biologists, immunologists, and geneticists from North America, the UK and Europe.

Over three days in the south of France, through presentations, work sessions, open discussions, and convivial lunches and dinners, the experts

  • assessed scientific progress – and failures – since the SMARCB1 gene was first discovered 25 years ago by Olivier Delattre and his team at Institut Curie in Paris

  • explored new approaches potentially conducive to the development of effective therapies

  • highlighted and discussed obstacles to the development of new therapies

  • discussed future research priorities that will lead to private and public funding for projects

  • planted seeds for future collaborations

F.Aguilhon/Reportagephotos.fr

May 2023 - Saint-Paul-de-Vence, France

F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
F.Aguilhon/Reportagephotos.fr
1 - 19

Meet the Attendees

2023 Symposium Program

Introduction
Olivier DelattreHistorical Background and Challenges Ahead
Chromatin Remodeling & Epigenetics – Towards Therapeutic Interventions
Charles RobertsSMARCB1-deficient cancers: mechanisms and vulnerabilities
Matthieu GérardSMARCB1 and BRG1 generate subnucleosomes that expand transcription factor binding and function at enhancers
Irwin DavidsonBRG1 in oncogenesis, the example of melanoma
Nada JabadoPRC1, PRC2, BAF and COMPASS complexes: it takes more than 2 to tango in pediatric high grade brain tumors
From Cell-of-Origin to Transformed Cells
Steve BaylinRoles for abnormal DNA methylation and chromatin remodeling in the origins of human cancer – from cell of origin to transformed cells
Sam BehjatiPhylogenetic approaches to finding the cell of origin of rhabdoid tumors
Jarno DrostPatient-specific epigenetic reprogramming drives malignant rhabdoid tumorigenesis
Franck BourdeautCell-of-origin – what mouse models can teach us
Constellation of SMARCB1/A4-deficient Tumors – Overlaps and Specificities
William Foulkes SMARCA4 – updates on associated phenotypes, plausible treatment targets and available resources
Sophie Postel-VinayEpithelioid sarcoma: exploring tumor heterogeneity
Thomas GrünewaldFunctional and translational genomics of Epithelioid sarcoma
Charles KellerFunctional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology
Martin HasselblattRare SMARCB1-deficient tumors of the CNS: Misfits or potential clues to a better understanding of rhabdoid tumor biology?
Gabriel MaloufRole of SMARCB1 alterations in renal medullary carcinomas
Josh SommerAccelerating rare cancer research — the Chordoma Foundation experience
Models, Stratification & Perspectives in Therapeutic Targetting
Annie Huang ATRTs sub-grouping – sufficient for therapeutic stratification?
Marcel KoolSingle cell transcriptional profiling of ATRTs
Paul HuangThe proteomic landscape of SMARCB1-deficient cancers
Dan WilliamsonSubgroup/location-independent prognostic signatures and their correlates in Malignant Rhabdoid Tumors
Mrinal GounderClinical Trials in SMARCB1 altered cancers – Past and Future Directions
Alex KentsisOvercoming clinical resistance to EZH2 inhibition of rhabdoid tumors using rational epigenetic combination therapy
Susan ChiEZH2 inhibition: the long journey of pediatric drug development
Michael FruehwaldRisk stratification in rhabdoid tumors – the need for novel markers AND therapies
Ulrich SchüllerComparative analysis of matched primary and relapsing atypical teratoid/rhabdoid tumors (AT/RT)
The Tumor Cell in its “Omic” & Microenvironment Contexts
Emmanuel DonnadieuImaging of failure and success of CAR T-cells in human tumors
Daniel de CarvalhoViral mimicry response to EZH2 inhibition in SMARCB1-deficient cancers
Eliane PiaggioImmunotherapy of RT: a translational approach
Josh WaterfallTranscriptional dysregulation as a source of tumor specific antigens
David SourdiveSmart cells : an industrial perspective in adoptive cancer immunotherapy
Breakout Brainstorming Sessions